{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T16:20:58Z","timestamp":1794932458944,"version":"4.9.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T00:00:00Z","timestamp":1748044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T00:00:00Z","timestamp":1748044800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s13555-025-01442-x","type":"journal-article","created":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T15:01:18Z","timestamp":1748098878000},"page":"1941-1952","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Effectiveness of Tildrakizumab 200\u00a0mg in Moderate-to-Severe Plaque Psoriasis: A Multicenter Real-World Study Analyzing Patient Outcomes by Weight, PASI, BMI, and Previous Therapies"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8301-9206","authenticated-orcid":false,"given":"Emanuele","family":"Trovato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Bianchelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Odorici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo","family":"Cuccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito Giuseppe","family":"Di Lernia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Lasagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Manfredini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Nicolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Rech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Satolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Cartocci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Bardazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Campanati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,24]]},"reference":[{"issue":"19","key":"1442_CR1","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945\u201360. https:\/\/doi.org\/10.1001\/jama.2020.4006.","journal-title":"JAMA"},{"issue":"12","key":"1442_CR2","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1080\/14712598.2022.2093106","volume":"22","author":"E Trovato","year":"2022","unstructured":"Trovato E, Rubegni P, Prignano F. Place in therapy of anti-IL-17 and 23 in psoriasis according to the severity of comorbidities: a focus on cardiovascular disease and metabolic syndrome. Expert Opin Biol Ther. 2022;22(12):1443\u20138. https:\/\/doi.org\/10.1080\/14712598.2022.2093106.","journal-title":"Expert Opin Biol Ther"},{"key":"1442_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2147\/PTT.S328447","volume":"12","author":"B Blackstone","year":"2022","unstructured":"Blackstone B, Patel R, Bewley A. Assessing and improving psychological well-being in psoriasis: considerations for the clinician. Psoriasis (Auckl). 2022;12:25\u201333. https:\/\/doi.org\/10.2147\/PTT.S328447.","journal-title":"Psoriasis (Auckl)"},{"issue":"8","key":"1442_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.702776","volume":"10","author":"FM Ghazawi","year":"2021","unstructured":"Ghazawi FM, Mahmood F, Kircik L, et al. A review of the efficacy and safety for biologic agents targeting IL-23 in treating psoriasis with the focus on tildrakizumab. Front Med. 2021;10(8):702776. https:\/\/doi.org\/10.3389\/fmed.2021.702776.","journal-title":"Front Med"},{"key":"1442_CR5","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19117","author":"M Dragotto","year":"2023","unstructured":"Dragotto M, Capalbo E, Cartocci A, et al. Real-life effectiveness of risankizumab according to body mass index: results of an Italian Multicentre Retrospective Study. J Eur Acad Dermatol Venereol. 2023. https:\/\/doi.org\/10.1111\/jdv.19117.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1442_CR6","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jbspin.2018.03.007","volume":"86","author":"J Shan","year":"2019","unstructured":"Shan J, Zhang J. Impact of obesity on the efficacy of different biologic agents in inflammatory diseases: a systematic review and meta-analysis. Jt Bone Spine. 2019;86(2):173\u201383. https:\/\/doi.org\/10.1016\/j.jbspin.2018.03.007.","journal-title":"Jt Bone Spine"},{"issue":"1","key":"1442_CR7","doi-asserted-by":"publisher","first-page":"2420825","DOI":"10.1080\/09546634.2024.2420825","volume":"35","author":"A Dattola","year":"2024","unstructured":"Dattola A, Bernardini N, Svara F, et al. Effectiveness of tildrakizumab 200 mg: an Italian multicenter study. J Dermatolog Treat. 2024;35(1):2420825. https:\/\/doi.org\/10.1080\/09546634.2024.2420825.","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"1442_CR8","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1080\/14712598.2024.2325547","volume":"24","author":"P Dapavo","year":"2024","unstructured":"Dapavo P, Burlando M, Guarneri C, et al. Tildrakizumab: the value of a personalized and flexible approach for treating moderate-to-severe plaque psoriasis in patients with high body weight or high disease burden. Expert Opin Biol Ther. 2024;24(3):133\u20138. https:\/\/doi.org\/10.1080\/14712598.2024.2325547.","journal-title":"Expert Opin Biol Ther"},{"issue":"4","key":"1442_CR9","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.1404a284","volume":"14","author":"EV Di Brizzi","year":"2024","unstructured":"Di Brizzi EV, Caccavale S, Di Caprio R, et al. A prospective real-life multicenter study of tildrakizumab 200 mg in patients with moderate-severe psoriasis: who is the ideal patient? Dermatol Pract Concept. 2024;14(4):e2024284. https:\/\/doi.org\/10.5826\/dpc.1404a284.","journal-title":"Dermatol Pract Concept"},{"issue":"3","key":"1442_CR10","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.orcp.2023.05.004","volume":"17","author":"H Kim","year":"2023","unstructured":"Kim H, Hong JY, Cheong S, Kang JH. Impact of biologic agents on body weight and obesity-related disorders in patients with psoriasis: a nationwide population-based cohort study. Obes Res Clin Pract. 2023;17(3):210\u20137. https:\/\/doi.org\/10.1016\/j.orcp.2023.05.004.","journal-title":"Obes Res Clin Pract"},{"issue":"10","key":"1442_CR11","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1007\/s13555-022-00793-z","volume":"12","author":"D Tha\u00e7i","year":"2022","unstructured":"Tha\u00e7i D, Gerdes S, Gaarn Du Jardin K, Perrot JL, Puig L. Efficacy of tildrakizumab across different body weights in moderate-to-severe psoriasis over 5\u00a0years: pooled analyses from the reSURFACE pivotal studies. Dermatol Ther (Heidelb). 2022;12(10):2325\u201341. https:\/\/doi.org\/10.1007\/s13555-022-00793-z.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1442_CR12","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2023-12-5","author":"T Torres","year":"2024","unstructured":"Torres T, Varela P, Mendes Bastos P, Magina S, Henrique M, Ferreira P. Tildrakizumab for the treatment of moderate-to-severe psoriasis: a 52-week, real-world Portuguese multicentric study. Drugs Context. 2024. https:\/\/doi.org\/10.7573\/dic.2023-12-5.","journal-title":"Drugs Context"},{"issue":"6","key":"1442_CR13","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1111\/jdv.15400.0","volume":"33","author":"KA Papp","year":"2019","unstructured":"Papp KA, Reich K, Blauvelt A, et al. Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks\u00a012 and 28. J Eur Acad Dermatol Venereol. 2019;33(6):1098\u2013106. https:\/\/doi.org\/10.1111\/jdv.15400.0.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"17","key":"1442_CR14","doi-asserted-by":"publisher","first-page":"5240","DOI":"10.3390\/jcm13175240","volume":"13","author":"E Trovato","year":"2024","unstructured":"Trovato E, Dragotto M, Capalbo E, Cartocci A, Rubegni P, Calabrese L. Uncovering the differences: how DLQI and WHO-5 scores vary in moderate-to-severe psoriasis patients treated with tildrakizumab 100 mg vs. 200 mg? J Clin Med. 2024;13(17):5240. https:\/\/doi.org\/10.3390\/jcm13175240.","journal-title":"J Clin Med"},{"issue":"11","key":"1442_CR15","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.1016\/j.ajpath.2015.07.006","volume":"185","author":"G K\u00f5ks","year":"2015","unstructured":"K\u00f5ks G, Uudelepp ML, Limbach M, Peterson P, Reimann E, K\u00f5ks S. Smoking-induced expression of the GPR15 gene indicates its potential role in chronic inflammatory pathologies. Am J Pathol. 2015;185(11):2898\u2013906. https:\/\/doi.org\/10.1016\/j.ajpath.2015.07.006.","journal-title":"Am J Pathol"},{"issue":"1","key":"1442_CR16","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jdermsci.2008.03.013","volume":"52","author":"K Kingo","year":"2008","unstructured":"Kingo K, Aunin E, Karelson M, et al. Expressional changes in the intracellular melanogenesis pathways and their possible role in the pathogenesis of vitiligo. J Dermatol Sci. 2008;52(1):39\u201346. https:\/\/doi.org\/10.1016\/j.jdermsci.2008.03.013.","journal-title":"J Dermatol Sci"},{"issue":"1","key":"1442_CR17","doi-asserted-by":"publisher","first-page":"2350760","DOI":"10.1080\/09546634.2024.2350760","volume":"35","author":"L Gargiulo","year":"2024","unstructured":"Gargiulo L, Ibba L, Cascio Ingurgio R, et al. Comparative effectiveness of tildrakizumab 200\u00a0mg versus tildrakizumab 100\u00a0mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study\u2014IL PSO (Italian Landscape Psoriasis). J Dermatolog Treat. 2024;35(1):2350760.","journal-title":"J Dermatolog Treat"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01442-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01442-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01442-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T06:00:37Z","timestamp":1748671237000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01442-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,24]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1442"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01442-x","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,24]]},"assertion":[{"value":"2 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Anna Campanati is an Editorial Board member of\n                      Dermatology and Therapy\n                      . Anna Campanati was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Emanuele Trovato has nothing to disclose. Tommaso Bianchelli has nothing to disclose. Giulia Odorici has nothing to disclose. Aldo Cuccia has nothing to disclose. Vito Giuseppe Di Lernia has nothing to disclose. Claudia Lasagni has nothing to disclose. Marco Manfredini has nothing to disclose. Massimiliano Nicolini has nothing to disclose. Giulia Rech has nothing to disclose. Francesca Satolli has nothing to disclose. Alessandra Cartocci has nothing to disclose. Federico Bardazzi has nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki (1964 and subsequent amendments) and it was approved by the local ethics committee (N\u00b0\u00a022045).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}